세계의 면역단백질 진단검사 시장 - 규모, 점유율, 동향 분석 보고서 : 검사별, 기술별, 최종 용도별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Immunoprotein Diagnostic Testing Market Size, Share & Trends Analysis Report By Test (Immunoglobulin Diagnostic Tests), By Technology, By Application, By Distribution Channel, By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,302,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,698,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,488,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

면역단백질 진단검사 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계 면역단백질 진단검사 시장 규모는 2025-2030년 동안 7.7%의 연평균 복합 성장률(CAGR)을 기록해, 2030년에는 148억 6,000만 달러에 이를 전망입니다. 이 성장은 만성 질환의 이환율 증가로 인한 것입니다.

미국 심장협회의 2017년 통계에 따르면, 미국에서는 매년 79만명 가까이 심장 발작을 경험하고 있으며, 또한 뇌졸중은 미국에서 사망자 20명 중 1명의 원인이 되고 있습니다. 앞서 언급한 요인의 결과로 신속한 진단을 촉진하기 위해 면역단백질 진단에 대한 수요가 증가할 것으로 예상됩니다.

WHO에 따르면 2015년에는 세계 폐암에 의한 사망이 169만명 가까이 등록되어 있습니다. 따라서 이러한 만성 질환의 신속하고 정확한 진단은 높은 사망률을 줄이는 데 중요합니다. 면역단백질 진단 장치와 시약은 만성 질환을 신속하게 검출하는데 매우 효과적인 것으로 입증되었습니다.

면역단백질 진단 부문에서 기술의 진보는 새로운 제품의 채택 연결되어 있습니다. 예를 들어, DiaSorin의 LIAISON XL은 완전 자동화학 발광 분석기로 완전한 시료 처리를 용이하게 합니다. 또한 검사 샘플을 측정하고 평가함으로써 시스템의 효율과 처리량을 향상시킵니다.

면역단백질 진단검사 시장 보고서 하이라이트

• 면역글로불린 진단검사 부문은 2024년 27.1% 시장 최대 수익 점유율을 차지했습니다. 이러한 검사는 면역결핍, 자가면역 질환 및 감염을 포함한 광범위한 질병의 진단에 중요한 역할을 하기 때문에 면역단백질 진단검사 시장을 독점하고 있습니다.
• 감염증 검사 부문은 2024년 24.2% 시장 최대 판매 점유율을 차지했습니다. 감염증 검사는 감염증의 유병률 증가, 조기 및 정확한 진단의 필요성, 공중 보건 관리에서 이러한 검사가 수행하는 중요한 역할로 인해 높은 수요가 있습니다.
• 2024년에는 효소 기반 면역분석 세분화가 25.0%로 시장에서 가장 큰 수익 점유율을 차지했습니다.
• 소매 판매 부문은 2024년 54.1%의 최대 점유율을 차지했습니다. 이러한 성장은 환자의 접근성과 편리성의 향상에 기인합니다.
• 병원 및 클리닉 부문은 2024년에 44.7%로 시장에서 가장 큰 매출 점유율을 차지했습니다. 병원이나 클리닉에서는 매일 다수의 환자가 진찰하기 때문에 진단검사 서비스에 대한 수요가 높아지고 있습니다.
• 북미의 면역단백질 진단검사 산업이 우세했고, 2024년에는 45.32%의 점유율을 차지했습니다. 시장의 이점은 기술의 진보, 만성 질환의 높은 유병률, 연구 개발에 대한 투자 확대로 인한 것입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 면역단백질 진단검사 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 면역단백질 진단검사 시장 분석 툴
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 면역단백질 진단검사 시장 : 검사별, 추정·동향 분석

• 검사 시장 점유율, 2024년과 2030년
• 부문 대시보드
• 검사에 의한 세계의 면역단백질 진단검사 시장 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
  • 보체계 단백질 진단검사
  • 유리경쇄검사
  • 합토글로빈 진단검사
  • 면역글로불린 진단검사
  • 프리알부민 진단검사
  • C 반응성 단백질(CRP) 진단검사

제5장 면역단백질 진단검사 시장 : 용도별, 추정·동향 분석

• 용도 시장 점유율, 2024년과 2030년
• 부문 대시보드
• 용도에 의한 세계의 면역단백질 진단검사 시장 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
  • 감염증 검사
  • 종양학 검사
  • 내분비 검사
  • 독성 검사
  • 알레르기 검사
  • 자가면역질환검사

제6장 면역단백질 진단검사 시장 : 기술별, 추정·동향 분석

• 기술 시장 점유율, 2024년과 2030년
• 부문 대시보드
• 기술에 의한 세계의 면역단백질 진단검사 시장 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
  • 방사면역측정
  • 효소 면역 측정법
  • 화학발광 검정
  • 면역형광 검정
  • 면역탁도 검정
  • 면역단백질 전기영동

제7장 면역단백질 진단검사 시장 : 최종 용도별, 추정·동향 분석

• 최종 용도 시장 점유율, 2024년과 2030년
• 부문 대시보드
• 최종 용도에 의한 세계의 면역단백질 진단검사 시장 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
  • 병원 및 클리닉
  • 진단 실험실
  • 기타

제8장 면역단백질 진단검사 시장 : 유통 채널별, 추정·동향 분석

• 유통 채널 시장 점유율, 2024년과 2030년
• 부문 대시보드
• 유통 채널에 의한 세계의 면역단백질 진단검사 시장 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
  • 직접 입찰
  • 소매 판매

제9장 면역단백질 진단검사 시장 :지역별, 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 세계 지역 시장 현황
• 시장 규모와 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제10장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업/경쟁의 분류
• 벤더 상황
  • 주요 기업의 시장 점유율 분석, 2024년
  • Agilent Technologies, Inc.
  • Danaher Corporation
  • Thermo Fisher Scientific Inc
  • PerkinElmer Inc
  • Bio-Rad Laboratories, Inc
  • Aurora Biomed Inc.
  • Tecan Trading AG
  • Promega Corporation
  • Charles River Laboratories
  • Creative Biolabs

JHS

영문 목차

영문목차

Immunoprotein Diagnostic Testing Market Growth & Trends:

The global Immunoprotein Diagnostic testing market size is expected to reach USD 14.86 billion by 2030, registering a CAGR of 7.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth can be attributed to the rising incidence of chronic diseases.

According to American Heart Association's 2017 statistics, nearly 790,000 people experience heart attack every year in the U.S. In addition, stroke is responsible for 1 in every 20 deaths in the U.S. Hence, WHO is also taking initiatives to reduce the risk of cardiovascular diseases. As a result of the aforementioned factors, the demand for Immunoprotein Diagnostic is expected to rise in order to facilitate rapid diagnosis.

According to WHO, nearly 1.69 million deaths due to lung cancer were registered in 2015 throughout the world. Hence, fast and accurate diagnosis of such chronic diseases has become important to reduce the high mortality rate. Immunoprotein diagnostic devices and reagents have proved to be highly effective in rapidly detecting chronic diseases.

Technological advancements in the field of Immunoprotein Diagnostic have led to introduction of novel products. For instance, LIAISON XL, manufactured by DiaSorin, is a fully automated chemiluminescence analyzer that facilitates complete sample processing. It also measures and evaluates testing samples, thereby, enhancing the efficiency and throughput of the system.

Immunoprotein Diagnostic Testing Market Report Highlights:

• The immunoglobulin diagnostic tests segment accounted for the largest revenue share of the market of 27.1% in 2024. These tests dominate the immunoprotein diagnostic testing market due to their critical role in diagnosing a wide range of conditions, including immune deficiencies, autoimmune disorders, and infectious diseases.
• The infectious disease testing segment accounted for the largest revenue share of the market of 24.2% in 2024. Infectious disease testing is in high demand due to the increasing prevalence of infectious diseases, the need for early and accurate diagnosis, and the critical role these tests play in managing public health.
• The enzyme-based immunoassay segment accounted for the largest revenue share of the market of 25.0% in 2024.
• The retail sales segment accounted for the largest share of the market of 54.1% in 2024. This growth can be attributed to the increased accessibility and convenience for patients.
• The hospitals and clinics segment accounted for the largest revenue share of the market of 44.7% in 2024. Hospitals and clinics serve a large number of patients daily, driving a high demand for diagnostic testing services.
• North America immunoprotein diagnostic testing industry dominated and accounted for a 45.32% share in 2024. The market dominance can be attributed to technological advancements, the high prevalence of chronic diseases, and growing investments in research and development.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Test
  • 1.2.2. Application
  • 1.2.3. Technology
  • 1.2.4. End Use
  • 1.2.5. Distribution Channel
  • 1.2.6. Regional scope
  • 1.2.7. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Test outlook
  • 2.2.2. Application outlook
  • 2.2.3. Technology outlook
  • 2.2.4. End Use outlook
  • 2.2.5. Distribution channel outlook
  • 2.2.6. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Immunoprotein Diagnostic Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Prevalence of Chronic Diseases
    • 3.2.1.2. Technological Advancements
    • 3.2.1.3. Growing Focus on Personalized Medicine
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Diagnostic Tests
    • 3.2.2.2. Regulatory Challenges
• 3.3. Immunoprotein Diagnostic Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Immunoprotein Diagnostic Testing Market: Test Estimates & Trend Analysis

• 4.1. Test Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Immunoprotein Diagnostic Testing Market by Test Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Complement System Proteins Diagnostic Tests
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Free Light Chain Diagnostic Tests
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Haptoglobin Diagnostic Tests
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Immunoglobulin Diagnostic Tests
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Prealbumin Diagnostic Tests
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.6. C-Reactive Protein (CRP) Diagnostic Tests
    • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Immunoprotein Diagnostic Testing Market: Application Estimates & Trend Analysis

• 5.1. Application Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Immunoprotein Diagnostic Testing Market by Application Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Infectious Disease Testing
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Oncology Testing
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Endocrine Testing
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Toxicology Testing
    • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. Allergy Testing
    • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.6. Autoimmune Disease Testing
    • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Immunoprotein Diagnostic Testing Market: Technology Estimates & Trend Analysis

• 6.1. Technology Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Immunoprotein Diagnostic Testing Market by Technology Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Radioimmunoassay
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Enzyme Based Immunoassay
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Chemiluminescence Assay
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Immunofluorescence Assay
    • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Immunoturbidity Assay
    • 6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Immunoprotein Electrophoresis
    • 6.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Immunoprotein Diagnostic Testing Market: End Use Estimates & Trend Analysis

• 7.1. End Use Market Share, 2024 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Immunoprotein Diagnostic Testing Market by End Use Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Hospitals and Clinics
    • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Diagnostic Laboratories
    • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Others
    • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Immunoprotein Diagnostic Testing Market: Distribution Channel Estimates & Trend Analysis

• 8.1. Distribution Channel Market Share, 2024 & 2030
• 8.2. Segment Dashboard
• 8.3. Global Immunoprotein Diagnostic Testing Market by Distribution Channel Outlook
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.4.1. Direct Tender
    • 8.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Retail Sales
    • 8.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Immunoprotein Diagnostic Testing Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Global Regional Market Snapshot
• 9.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 9.5. North America
  • 9.5.1. U.S.
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/ reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. Target disease prevalence
    • 9.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.2. Canada
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/ reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. Target disease prevalence
    • 9.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.3. Mexico
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/ reimbursement structure
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. Target disease prevalence
    • 9.5.3.5. Mexico market estimates and forecasts 2018 to 2030, (USD Million
• 9.6. Europe
  • 9.6.1. UK
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/ reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. Target disease prevalence
    • 9.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.2. Germany
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Target disease prevalence
    • 9.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.3. France
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework/ reimbursement structure
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Target disease prevalence
    • 9.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.4. Italy
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework/ reimbursement structure
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. Target disease prevalence
    • 9.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.5. Spain
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework/ reimbursement structure
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Target disease prevalence
    • 9.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.6. Norway
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Regulatory framework/ reimbursement structure
    • 9.6.6.3. Competitive scenario
    • 9.6.6.4. Target disease prevalence
    • 9.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.7. Sweden
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Regulatory framework/ reimbursement structure
    • 9.6.7.3. Competitive scenario
    • 9.6.7.4. Target disease prevalence
    • 9.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.8. Denmark
    • 9.6.8.1. Key country dynamics
    • 9.6.8.2. Regulatory framework/ reimbursement structure
    • 9.6.8.3. Competitive scenario
    • 9.6.8.4. Target disease prevalence
    • 9.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 9.7. Asia Pacific
  • 9.7.1. Japan
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/ reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. Target disease prevalence
    • 9.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.2. China
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Target disease prevalence
    • 9.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.3. India
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/ reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. Target disease prevalence
    • 9.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.4. Australia
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/ reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Target disease prevalence
    • 9.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.5. South Korea
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Regulatory framework/ reimbursement structure
    • 9.7.5.3. Competitive scenario
    • 9.7.5.4. Target disease prevalence
    • 9.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.6. Thailand
    • 9.7.6.1. Key country dynamics
    • 9.7.6.2. Regulatory framework/ reimbursement structure
    • 9.7.6.3. Competitive scenario
    • 9.7.6.4. Target disease prevalence
    • 9.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.8. Latin America
  • 9.8.1. Brazil
    • 9.8.1.1. Key country dynamics
    • 9.8.1.2. Regulatory framework/ reimbursement structure
    • 9.8.1.3. Competitive scenario
    • 9.8.1.4. Target disease prevalence
    • 9.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.2. Argentina
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework/ reimbursement structure
    • 9.8.2.3. Competitive scenario
    • 9.8.2.4. Target disease prevalence
    • 9.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.9. MEA
  • 9.9.1. South Africa
    • 9.9.1.1. Key country dynamics
    • 9.9.1.2. Regulatory framework/ reimbursement structure
    • 9.9.1.3. Competitive scenario
    • 9.9.1.4. Target disease prevalence
    • 9.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.2. Saudi Arabia
    • 9.9.2.1. Key country dynamics
    • 9.9.2.2. Regulatory framework/ reimbursement structure
    • 9.9.2.3. Competitive scenario
    • 9.9.2.4. Target disease prevalence
    • 9.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.3. UAE
    • 9.9.3.1. Key country dynamics
    • 9.9.3.2. Regulatory framework/ reimbursement structure
    • 9.9.3.3. Competitive scenario
    • 9.9.3.4. Target disease prevalence
    • 9.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.4. Kuwait
    • 9.9.4.1. Key country dynamics
    • 9.9.4.2. Regulatory framework/ reimbursement structure
    • 9.9.4.3. Competitive scenario
    • 9.9.4.4. Target disease prevalence
    • 9.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. Key company market share analysis, 2024
  • 10.3.2. Agilent Technologies, Inc.
    • 10.3.2.1. Company overview
    • 10.3.2.2. Financial performance
    • 10.3.2.3. Product benchmarking
    • 10.3.2.4. Strategic initiatives
  • 10.3.3. Danaher Corporation
    • 10.3.3.1. Company overview
    • 10.3.3.2. Financial performance
    • 10.3.3.3. Product benchmarking
    • 10.3.3.4. Strategic initiatives
  • 10.3.4. Thermo Fisher Scientific Inc
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Product benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. PerkinElmer Inc
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Product benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Bio-Rad Laboratories, Inc
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Product benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. Aurora Biomed Inc.
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Product benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. Tecan Trading AG
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Product benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Promega Corporation
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Product benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. Charles River Laboratories
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Product benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. Creative Biolabs
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Product benchmarking
    • 10.3.11.4. Strategic initiatives

관련자료